Showing results (1841-1850 of 2,473) with videos related to

Sort By:
Pageof 248
Cancer Treatment Reviews|October 10, 2020
Association of immune checkpoint inhibitors with respiratory infections: A reviewRyosuke Hamashima, Junji Uchino, Yoshie Morimoto, et al.
Cancer Treatment Reviews|June 21, 2021
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysisKeiichiro Mori, Benjamin Pradere, Fahad Quhal, et al.
Cancer Treatment Reviews|June 22, 2021
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good newsFrancisco Zambrana, Lucia Carril-Ajuria, Alfonso Gómez de Liaño, et al.
Cancer Treatment Reviews|January 12, 2023
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapiesElizabeth Smyth, Chan Y Cheah, John F Seymour
Cancer Treatment Reviews|January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewF Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews|January 14, 2023
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neckRobert L Ferris, Kevin Harrington, Jonathan D Schoenfeld, et al.
Cancer Treatment Reviews|January 1, 2023
Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidenceArndt Vogel, Sebastian Ochsenreither, Jonathan S Zager, et al.
Cancer Treatment Reviews|June 27, 2022
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trialsNavid Sobhani, Bruna Scaggiante, Rachel Morris, et al.
Cancer Treatment Reviews|May 25, 2019
Hedgehog signaling inhibitors in solid and hematological cancersJorge E Cortes, Ralf Gutzmer, Mark W Kieran, et al.
Cancer Treatment Reviews|October 11, 2021
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitorsM Bartoletti, L Musacchio, G Giannone, et al.
Pageof 248